ArticleClinical medicine insights. Case reports2025
Primary Amyloidosis Unmasked by Gastric Biopsy: A Case Report.
Article in Clinical medicine insights. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amyloidosis with predominant gastrointestinal symptoms: a challenge for physicians and a burden for patients: a case report.Journal of medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloidosis is a broad category of diseases characterized by the extracellular accumulation of misfolded fibrillar proteins, which disrupt organ architecture and causes cellular toxicity. This ultimately results in vascular compromise and progressive organ dysfunction. Despite advances in serum free light chain assays and imaging modalities, diagnostic delays persist due to the underestimation of early signs and the need for multidisciplinary correlation. Our case report highlights a unique case of a patient with systemic AL amyloidosis involving the gastrointestinal (GI) system, who initially presented with chronic diarrhea and profound weight loss. We emphasize the diagnostic challenges in recognizing multiorgan amyloidosis, underscore the role of histopathology and advanced imaging in confirming systemic spread, and discuss the clinical implications of concurrent GI disease. In this piece, we also discuss the therapeutic treatment of amyloidosis including chemotherapy and supportive care for the major presenting symptom, diarrhea. The key lesson of our case is the importance of having a high clinical suspicion of amyloidosis in patients with unexplained GI symptoms, especially diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.